Cover Story: Fat chance for cancer cachexia

Table 1. Cancer-associated cachexia products in clinical development. Although two compounds failed in Phase III trials for cancer
cachexia, the landscape is still full of companies working to develop therapeutics for the cancer-associated form of the disease. At least
12 companies have therapeutics in clinical development for the indication. Because of the heterogeneity of the disease, multiple treatments may be needed to address cachexia caused by different types of cancer.
Source: BCIQ: BioCentury Online Intelligence

Company

Product

Description

Phase of development

Helsinn Healthcare S.A.; Chugai Pharmaceutical Co. Ltd. (Tokyo:4519); Especificos Stendhal S.A. de C.V.; Gruppo Angelini; Ono Pharmaceutical Co. Ltd. (Tokyo:4528); Specialised Therapeutics Australia Pty. Ltd.

Anamorelin

Small molecule ghrelin mimetic

Phase III

XBiotech Inc.

CA-18C3

Human mAb against IL-1a

Phase III

Acacia Pharma Ltd.

APD209

Oral fixed-dose combination of progestin and the selective adrenergic receptor b2 (ADRB2) agonist formoterol

Phase II

Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS)

AEZS-130

Oral ghrelin mimetic that acts as a growth hormone secretagogue

Phase II

Akela Pharma Inc.

GHRH analog

Peptide analog of growth hormone-releasing hormone (GHRH)

Phase II

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR)

Clazakizumab

Humanized mAb against IL-6

Phase II

Novartis AG (NYSE:NVS; SIX:NOVN)

Bimagrumab

Human mAb against activin receptor type 2B (ACVR2B)

Phase II

Ohr Pharmaceutical Inc. (NASDAQ:OHRP)

OHR/AVR118

Broad-spectrum peptide nucleic acid immunomodulator

Phase II

PsiOxus Therapeutics Ltd.

MT-102

Dual-action anabolic and catabolic transforming agent with ADRB antagonist activity

Phase II

Rose Pharma A/S

GTP-200

Ghrelin-based compound

Phase II

GTP-300

Ghrelin peptide

Vicus Therapeutics LLC

VT-122

Fixed-dose combination of propranolol, a nonselective ADRB blocker, and the cyclooxygenase-2 (COX-2) inhibitor etodolac

Phase II

Ligand Pharmaceuticals Inc. (NASDAQ:LGND)

YK5211

Nonsteroidal selective androgen receptor modulator

Phase I